title: Minimal Residual Disease in Acute Myeloid Leukemia.
abstract: New technology and improved understanding of the pathogenesis of acute leukemias have allowed for sensitive detection of minimal residual disease (MRD). Despite many years of research demonstrating the prognostic value of MRD, there is no standard of care for measurement of MRD in acute myeloid leukemia. The techniques for assessment are continuing to improve at a rapid pace; however, the benefit of risk-adapted approaches for MRD positive disease remains a major question. This review focuses on recent methodological advances for MRD detection, the role of MRD in prognostication, and current application of the available evidence in guiding therapy decisions.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd., South Pavilion 12th floor, Philadelphia, PA, 19104, USA.
authors.forename: Pamela J
authors.initials: PJ
authors.lastname: Sung
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd., South Pavilion 12th floor, Philadelphia, PA, 19104, USA. Selina.Luger@uphs.upenn.edu.
authors.forename: Selina M
authors.initials: SM
authors.lastname: Luger
mesh_terms: D014408:Biomarkers, Tumor; D000066491:Clinical Decision-Making; D019468:Disease Management; D005434:Flow Cytometry / Q000379:methods; D023281:Genomics / Q000379:methods; D006801:Humans; D016130:Immunophenotyping / Q000379:methods; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D025202:Molecular Diagnostic Techniques; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor
keywords: Acute myeloid leukemia; Minimal residual disease; Risk-adapted approach